| 注册
首页|期刊导航|中西医结合肝病杂志|补肾法治疗慢性HBV携带者的多中心、随机、双盲、安慰剂对照临床研究

补肾法治疗慢性HBV携带者的多中心、随机、双盲、安慰剂对照临床研究

袁艺梦 陆定波 胡振斌 蒋开平 李丰衣 潘小平 周晓玲 蔡庆贤 祝俊峰 聂可莹 韩志毅 邢宇锋 赵钢 杨志云 郭朋 王丽春 靳华

中西医结合肝病杂志2026,Vol.36Issue(4):397-401,5.
中西医结合肝病杂志2026,Vol.36Issue(4):397-401,5.DOI:10.3969/j.issn.1005-0264.2026.004.001

补肾法治疗慢性HBV携带者的多中心、随机、双盲、安慰剂对照临床研究

A multicenter,randomized,double-blind,placebo-controlled clinical trial evalua-ting the efficacy of the Bushen method in chronic hepatitis B virus carriers

袁艺梦 1陆定波 2胡振斌 3蒋开平 4李丰衣 5潘小平 6周晓玲 7蔡庆贤 8祝俊峰 9聂可莹 1韩志毅 1邢宇锋 1赵钢 10杨志云 11郭朋 12王丽春 13靳华14

作者信息

  • 1. 广州中医药大学第四临床医学院(广东 深圳,518033)
  • 2. 湖北省中医院肝病科
  • 3. 广西中医药大学第一附属医院肝病科
  • 4. 佛山市中医院肝病科
  • 5. 解放军总医院第五医学中心感染病医学部
  • 6. 浙江中医药大学基础医学院
  • 7. 柳州市中医医院肝病科
  • 8. 深圳市第三人民医院肝脏肿瘤科
  • 9. 上海市中医医院肝病科
  • 10. 上海中医药大学附属曙光医院肝病科
  • 11. 首都医科大学附属北京地坛医院肝病科
  • 12. 中国中医科学院西苑医院肝病科
  • 13. 四川大学华西医院感染疾病中心
  • 14. 首都医科大学附属北京佑安医院中西医肝病科
  • 折叠

摘要

Abstract

Objective:The objective of this study was to evaluate and compare the clinical efficacy of Bushen Shugan Decoction and Bushen Jianpi Decoction in chronic hepatitis B virus(HBV)carriers.Methods:From November 2018 to December 2021,a total of 362 chronic HBV carriers aged between 30 and 65 years were enrolled across 14 clinical centers in China.Participants were randomly assigned to three treatment groups:Group A received the Bushen Shugan Decoction,Group B received the Bushen Jianpi Decoction,and Group C received a placebo.Unblinded after 96 weeks of treatment and followed up for another 48 weeks.The primary outcome measures included serological response rates for HBsAg and HBeAg,as well as rates of HBV DNA suppression at week 48.Results:A total of 362 subjects were enrolled in the study,and 353 completed the 48-week treatment regimen.The distribution included 120 in Group A,115 in Group B,and 118 in Group C.In Groups A and B,the proportions of patients exhibiting a reduction in HBV DNA quantification of ≥ 2.0 lg IU/ml were 15.00% and 17.39%,respectively.The proportions of patients achieving HBV DNA levels ≤4.0 lg IU/ml were 9.17% and 13.91%,respectively.HBeAg seroconversion rates were observed in 7.5% of Group A and 11.3% of Group B.Furthermore,the proportions of patients with HBsAg reduction ≥1.0 lg IU/ml were 6.67% and 9.57%,respectively,while reductions of ≥2.0 lg IU/ml were recorded at 4.17% and 5.22%.All these outcomes showed statistically significant differences compared with Group C(P<0.05).Conclusion:The Bushen therapeutic strategy demonstrates a notable clinical benefit for chronic HBV carriers.Moreover,the optimized formula integrating Bushen and Jianpi approaches shows superior efficacy compared to the combination of Bushen and Shugan strategies.

关键词

慢性HBV感染/补肾疏肝/补肾健脾/随机对照试验

Key words

chronic hepatitis B virus carrier/Bushen Shugan/Bushen Jianpi/randomized controlled trial

分类

医药卫生

引用本文复制引用

袁艺梦,陆定波,胡振斌,蒋开平,李丰衣,潘小平,周晓玲,蔡庆贤,祝俊峰,聂可莹,韩志毅,邢宇锋,赵钢,杨志云,郭朋,王丽春,靳华..补肾法治疗慢性HBV携带者的多中心、随机、双盲、安慰剂对照临床研究[J].中西医结合肝病杂志,2026,36(4):397-401,5.

基金项目

国家"十三五"科技重大专项(No.2018ZX10725505-002) (No.2018ZX10725505-002)

中西医结合肝病杂志

1005-0264

访问量0
|
下载量0
段落导航相关论文